Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.96 USD | +5.29% | -28.89% | -13.09% |
13/05 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
08/05 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.09% | 244M | |
+13.12% | 227B | |
+13.93% | 192B | |
+17.33% | 136B | |
+28.50% | 108B | |
+1.67% | 64.07B | |
+17.54% | 52.1B | |
+7.04% | 51.87B | |
+10.88% | 44.33B | |
+5.48% | 36.75B |
- Stock Market
- Equities
- NPCE Stock
- News NeuroPace, Inc.
- Transcript : NeuroPace, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07